Aprea Therapeutics, Inc.
APRE
$1.68
$0.085.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -34.08% | 33.26% | 157.60% | 130.31% | 410.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.08% | 33.26% | 157.60% | 130.31% | 410.93% |
| Cost of Revenue | 15.31% | 28.54% | 22.76% | 48.04% | 63.00% |
| Gross Profit | -24.24% | -27.89% | -11.60% | -39.60% | -45.12% |
| SG&A Expenses | -15.50% | -9.98% | -23.36% | -21.06% | -30.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.08% | 10.54% | -1.45% | 7.07% | 0.61% |
| Operating Income | -4.24% | -8.97% | 7.45% | -2.21% | 6.16% |
| Income Before Tax | -7.13% | -10.73% | 9.30% | -1.67% | 8.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.13% | -10.73% | 9.30% | -1.67% | 8.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.13% | -10.73% | 9.30% | -1.67% | 8.35% |
| EBIT | -4.24% | -8.97% | 7.45% | -2.21% | 6.16% |
| EBITDA | -4.22% | -8.92% | 7.55% | -2.08% | 6.27% |
| EPS Basic | 23.79% | 28.85% | 40.52% | 29.63% | 44.46% |
| Normalized Basic EPS | 23.79% | 28.85% | 40.52% | 29.63% | 44.46% |
| EPS Diluted | 23.79% | 28.85% | 40.52% | 29.63% | 44.46% |
| Normalized Diluted EPS | 23.79% | 28.85% | 40.52% | 29.63% | 44.46% |
| Average Basic Shares Outstanding | 36.14% | 54.69% | 52.31% | 48.11% | 54.80% |
| Average Diluted Shares Outstanding | 36.14% | 54.69% | 52.31% | 48.11% | 54.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |